Claims

- 1. A method of treating an allergy in a subject susceptible to an anaphylactic allergic response to an allergen, the method comprising steps of:

 providing a composition comprising microorganisms that produce the allergen; and
 - administering the composition to the subject at an effective and non-toxic dose.
- 2. The method of claim 1, wherein in the step of providing, the microorganism is selected from the group consisting of: bacteria, fungi, viruses, algae, and protozoa.
- 3. The method of claim 1, wherein in the step of providing, the microorganism is selected from the group consisting of: gram-negative bacteria, gram-positive bacteria, and yeast.
- 4. The method of claim 1, wherein in the step of providing, the microorganism is selected from the group consisting of: E. coli, Lactococcus, Listeria, Vibrio, Salmonella and S. cerevisiae.
 - 5. The method of claim 1, wherein in the step of providing, the allergen is found in foods, venoms, or latex.
- 20 6. The method of claim 1, wherein in the step of providing, the allergen is a protein found in peanuts, milk, eggs, seafood, nuts, dairy products and fruit.
 - 7. The method of claim 1, wherein in the step of providing, the allergen is a protein found in bee venom.
 - 8. The method of claim 1, wherein in the step of providing, the allergen is Ara h 1, Ara h 2, Ara h 3, or a polypeptide portion thereof.
 - 9. The method of claim 1, wherein in the step of providing, the allergen is protein modified

5

10

to have a reduced ability to bind and crosslink IgE antibodies.

5

15

20

- 10. The method of claim 1, wherein in the step of providing, the microorganisms produce a portion of the allergen.
- 11. The method of claim 10, wherein in the step of providing, the portion of the allergen produced has a reduced number of IgE binding sites as compared to the allergen.
- 12. The method of claim 1, wherein in the step of providing, the allergen is a polypeptide 10 and production of the allergen is inducible; and wherein after the step of administering, the method further comprises the step of inducing expression of the polypeptide.
 - 13. The method of claim 12, wherein in the step of inducing, the polypeptide is secreted into a periplasm or secreted outside the cell.
 - 14. The method of claim 1, wherein the step of providing comprises providing a composition comprising gram-negative bacteria or yeast that secretes the allergen into a periplasm.
 - 15. The method of claim 1, wherein in the step of providing, the allergen is a small molecule.
 - 16. A composition comprising a microorganism that produces an allergen that elicits an anaphylactic allergic reaction in a subject allergic to the allergen.
 - 17. The composition of claim 16, wherein the allergen is a polypeptide or small molecule.
 - 18. The composition of claim 16, wherein the microorganism is selected from the group consisting of: bacteria, fungi, viruses, algae, and protozoa.
 - 19. The composition of claim 16, wherein the microorganism is selected from the group

consisting of: gram-negative bacteria, gram-positive bacteria, and yeast.

5

10

- 20. The composition of claim 16, wherein the microorganism is selected from the group consisting of: E. coli, Lactococcus, Listeria, Vibrio, Salmonella and S. cerevisiae
- 21. The composition of claim 16, wherein the allergen found in foods, venoms, or latex.
- 22. The composition of claim 16, wherein the allergen is an allergen found in peanuts, milk, eggs, seafood, nuts, dairy products and fruit.
- 23. The composition of claim 16, wherein the allergen found in bee venom.
- 24. The composition of claim 16, wherein the protein is Ara h 1, Ara h 2, Ara h 3, or a polypeptide portion thereof.
- 25. The composition of claim 16, wherein the allergen is modified to have a reduced ability to bind and crosslink IgE antibodies.
- 26. The composition of claim 16, wherein the microorganism produces a portion of the allergen.
 - 27. The composition of claim 16, wherein the portion of the allergen produced has a reduced number of IgE binding sites as compared to the allergen.
- 25 28. The composition of claim 16, wherein production of the allergen is inducible.
 - 29. The composition of claim 16, wherein the allergen is a polypeptide which is secreted into a periplasm or secreted outside the cell.

- 30. The composition of claim 16, wherein the microorganism is a gram-negative bacteria or yeast that secretes the allergen into a periplasm.
- 31. A pharmaceutical composition comprising microorganisms that produce an allergen that elicits an anaphylactic allergic response in a subject susceptible to the anaphylactic allergic response, and further comprises an pharmaceutically acceptible carrier.
 - 32. The pharmaceutical composition of claim 31, wherein the allergen is a polypeptide or a small molecule.
 - 33. The pharmaceutical composition of claim 31, wherein the microorganisms produce a portion of an allergen that elicits an anaphylactic allergic response in a subject susceptible to the anaphylactic allergic response.